Business Context and Reporting Period
This Form 8-K is a current report filed by Eyenovia, Inc. (trading symbol: EYEN) on June 25, 2019. The registrant is incorporated in Delaware and lists its common stock on the Nasdaq Capital Market. The filing addresses a specific corporate governance event rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 5.02 regarding the departure of a director and does not contain financial statements or performance data.
Material Changes
- Board Resignation: Shuhei Yoshida resigned from the Board of Directors effective immediately on June 25, 2019.
- Reason for Departure: The resignation was due to Mr. Yoshida's increasing responsibilities as President of Senju Pharmaceuticals Co., Ltd. ("Senju"), a major stockholder of the Company. The filing explicitly states there was no disagreement with the Company.
- Observer Appointment: The Board agreed to grant Takemasa Sugioka, Chief Operating Officer of Senju, the right to attend certain Board meetings as a non-voting and non-compensated observer.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or new risk factors. The only contingency noted is the transition of board representation from Mr. Yoshida to an observer from Senju Pharmaceuticals.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following Mr. Yoshida's resignation.
- Confirm the extent of Senju Pharmaceuticals' ownership stake in Eyenovia, Inc.
- Review subsequent filings to determine if the observer role for Takemasa Sugioka was formalized or if a new director was appointed to fill the vacancy.